CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

Farhad Ravandi,Andrew Wei,Hartmut Döhner,Hervé Dombret,Gert J. Ossenkoppele,Michael Pfeilstöcker,Felicitas Thol,Georg Feldman,Maria Teresa Voso,Paula Marlton,Michael Harvey,Valeria Santini,Luana Fianchi,Anna Candoni,Ignazia La Torre,Barry Skikne,Keshava Kumar,Qian Dong,C. L. Beach,Gail J. Roboz

CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

2020

7530Background: About 40-50% of older patients (pts) with AML attain complete remission (CR) with induction chemotherapy (IC) but relapse is common.Effective, well-tolerated maintenance treatment (...

Keywords:

Myeloid leukemia
Induction chemotherapy
Oncology
Internal medicine
Pathology
Maintenance therapy
first remission
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations